Gabriele Casirati, of Boston Children’s Hospital, Susan E. De Wolf, of Memorial Sloan Kettering Cancer Center, Stephen Persaud, of Washington University School of Medicine, and Abdur Rehman, of the University of Texas MD Anderson Cancer Center, were awarded DKMS’ research grant in honor of John A. Hansen.
First-line treatment with the triplet combination of encorafenib, cetuximab, and mFOLFOX6 significantly improved survival compared to the standard of care in patients with BRAF V600E-mutated metastatic colorectal cancer, according to new data from the phase III BREAKWATER trial led by researchers from the University of Texas MD Anderson Cancer Center.
